Additionally, anlotinib combined with TQB2450 (an anti-PD-L1 mAb) showed promising efficacy in another phase I trial involving patients with advanced CCA who had progressed, declined, or were ineligible for first-line chemotherapy. The gene discussed is CD274; the disease is cholangiocarcinoma.